View Older Stories View More Recent Stories

Jun 28, 2021 07:00AM Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Improved both Primary Cognitive and Secondary MDS-UPDRS Efficacy Endpoints with Significant Biomarker Correlation in Placebo-Controlled Phase
Jun 24, 2021 04:15PM Anavex Life Sciences Announces Closing of $50 Million Registered Direct Offering
Jun 22, 2021 07:01AM Anavex Life Sciences (AVXL) Announces $50 Million Registered Direct Offering of Common Stock
Jun 22, 2021 07:00AM Anavex Life Sciences Announces $50 Million Registered Direct Offering
Jun 21, 2021 07:10AM Anavex (AVXL) Announces ANAVEX2-73 Biomarker Correlated with Efficacy Endpoints in Placebo-Controlled U.S. Phase 2 Clinical Trial for Treatment of Adult Patients with Rett Syndrome
Jun 21, 2021 07:00AM Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Biomarker Correlated with Efficacy Endpoints in Placebo-Controlled U.S. Phase 2 Clinical Trial for the Treatment of Adult Patients with Rett
Jun 14, 2021 07:08AM Anavex Life Sciences (AVXL) Reports New Publication in Medical Journal Elucidating the Mechanism of ANAVEX®2-73 and ANAVEX 3-71 related to Treatment of Alzheimer's Disease
Jun 14, 2021 07:00AM Anavex Life Sciences Reports New Publication in Medical Journal Elucidating the Mechanism of ANAVEX®2-73 (blarcamesine) and ANAVEX®3-71 (AF710B) related to the Treatment of Alzheimer's Disease
Jun 8, 2021 07:00AM Anavex Life Sciences Announces Exceeding of Enrollment Target for the Precision Medicine ANAVEX®2-73 (blarcamesine) Phase 2b/3 Clinical Trial in Patients with Alzheimer’s Disease
Jun 3, 2021 07:00AM Anavex Life Sciences Announces Notice of Allowance for U.S. Patent Application ANAVEX®2-73 (blarcamesine) for the Treatment of Cardiac Dysfunctions
May 26, 2021 07:11AM Anavex Life Sciences (AVXL) Announces Appointment of Ms Jiong Ma, PhD to Board of Directors
May 26, 2021 07:00AM Anavex Life Sciences Announces Appointment of Ms Jiong Ma, PhD to Board of Directors
May 13, 2021 07:00AM Anavex Life Sciences Reports Fiscal 2021 Second Quarter Financial Results And Business Outlook
May 7, 2021 07:00AM Anavex Life Sciences Announces Participation at Precision in Clinical Trials Virtual Summit
May 6, 2021 07:00AM Anavex Life Sciences to Announce Fiscal 2021 Second Quarter Financial Results and Business Outlook on Thursday, May 13, 2021
May 5, 2021 07:00AM Anavex Life Sciences Appoints Former FDA Officer as Senior Vice President for Nonclinical Development
Apr 26, 2021 07:00AM Anavex Life Sciences to Present at the B. Riley Securities’ Virtual Neuroscience Conference
Apr 12, 2021 07:09AM Anavex Life Sciences (AVXL) Reports Results of Review by Independent DSMB for its Phase 2/3 Trials of ANAVEX®2-73 in Patients with Rett Syndrome
Apr 12, 2021 07:00AM Anavex Life Sciences Reports the Results of Review by the Independent Data Safety Monitoring Board for its Phase 2/3 Trials of ANAVEX®2-73 in Patients with Rett Syndrome
Apr 8, 2021 07:00AM Anavex Life Sciences to Present at the 20th Annual Needham Virtual Healthcare Conference
Apr 7, 2021 07:00AM Anavex Life Sciences Announces Participation at Upcoming World EPA - Evidence, Pricing and Access - Congress 2021
Mar 31, 2021 07:00AM Anavex Life Sciences Reports Data Review by the Independent Data Safety Monitoring Board for its Phase 2b/3 Clinical Trial of ANAVEX®2-73 in Patients with Alzheimer’s Disease
Mar 16, 2021 07:07AM Anavex (AVXL) Reports ANAVEX 2-73 featured as Disease-Modifying Small Molecule in Phase 3 Clinical Trials in New Publication in Medical Journal titled "Future Avenues for Alzheimer's Disease Detection
Mar 16, 2021 07:00AM Anavex Life Sciences Reports ANAVEX®2-73 (blarcamesine) featured as a Disease-Modifying Small Molecule in Phase 3 Clinical Trials in a New Publication in Medical Journal titled “Future Avenues for
Mar 4, 2021 07:00AM Anavex Life Sciences to Present at the H.C. Wainwright Global Life Sciences Conference
Feb 22, 2021 07:00AM Anavex Life Sciences Announces Participation at Upcoming Worldwide National Institutes of Health (NIH) Panel at Rare Disease Day®
Feb 19, 2021 07:00AM Anavex Life Sciences Announces Participation at Precision in Clinical Trials Virtual Summit
Feb 18, 2021 07:00AM Anavex Life Sciences to Present at the 10th Annual SVB Leerink Global Healthcare Conference on February 25, 2021
Feb 11, 2021 07:00AM Anavex Life Sciences Reports Fiscal 2021 First Quarter Financial Results And Business Outlook
Feb 8, 2021 07:00AM Anavex Life Sciences to Announce Fiscal 2021 First Quarter Financial Results and Business Outlook on Thursday, February 11, 2021
Jan 11, 2021 07:00AM Anavex Life Sciences Receives Michael J. Fox Foundation Grant for Clinical Study of ANAVEX®2-73 (blarcamesine) in People with Parkinson’s Disease
Jan 6, 2021 07:00AM Anavex Life Sciences to Present at the H.C. Wainwright Virtual BioConnect Conference
Dec 28, 2020 07:00AM Anavex Life Sciences Reports Fiscal 2020 Year End Financial Results And Clinical Program Updates
Dec 22, 2020 07:00AM Anavex Life Sciences to Announce Fiscal 2020 Year End Financial Results December 28th, 2020
Dec 21, 2020 07:00AM Anavex Life Sciences Announces Webinar on Rett Syndrome and ANAVEX®2-73 (Blarcamesine) Phase 2 Data hosted by Ladenburg Thalmann & Co.
Dec 15, 2020 07:03AM Anavex Life Sciences (AVXL) Reports ANAVEX2-73 (Blarcamesine) Meets Primary & Secondary Endpoints in Placebo-Controlled U.S. Phase 2 Clinical Trial
Dec 15, 2020 07:00AM Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Meets Primary and Secondary Endpoints in Placebo-Controlled U.S. Phase 2 Clinical Trial for the Treatment of Adult Patients with Rett Syndrom
Nov 30, 2020 07:03AM Anavex Life Sciences (AVXL) Announces Notice of Allowance for U.S. Patent Application with Expanding Claims Covering ANAVEX®2-73 for Treatment of Rett Syndrome and other Neurodevelopmental Disorders
Nov 30, 2020 07:00AM Anavex Life Sciences Announces Notice of Allowance for U.S. Patent Application with Expanding Claims Covering ANAVEX®2-73 (blarcamesine) for the Treatment of Rett Syndrome and other Neurodevelopmenta
Nov 25, 2020 07:00AM Anavex Life Sciences to Present at the Evercore ISI 3rd Annual HealthCONx Conference
Nov 6, 2020 10:46AM Anavex Life Sciences (AVXL) Proof of Concept Controlled Phase 2 Clinical Trial Data Evaluating ANAVEX®2-73 (blarcamesine) in Parkinson’s Disease Dementia Presented at CTAD
Nov 6, 2020 10:45AM Proof of Concept Controlled Phase 2 Clinical Trial Data Evaluating ANAVEX®2-73 (blarcamesine) in Parkinson’s Disease Dementia Presented at CTAD 2020 Conference
Oct 15, 2020 07:02AM Anavex Life Sciences (AVXL) Reports Positive Results from Proof of Concept controlled Phase 2 Clinical Trial Evaluating ANAVEX2-73 in Parkinson's Disease Dementia
Oct 15, 2020 07:00AM Anavex Life Sciences Announces Positive Results from Proof of Concept controlled Phase 2 Clinical Trial Evaluating ANAVEX®2-73 (blarcamesine) in Parkinson’s Disease Dementia
Sep 10, 2020 07:04AM Anavex Life Sciences (AVXL) Reports Completion of ANAVEX2-73 (blarcamesine) U.S. Phase 2 Rett Syndrome Clinical Trial
Sep 10, 2020 07:00AM Anavex Life Sciences Announces Completion of ANAVEX®2-73 (blarcamesine) U.S. Phase 2 Rett Syndrome Clinical Trial
Sep 8, 2020 07:00AM Anavex Life Sciences to Present at Upcoming Global Healthcare Conferences
Aug 19, 2020 07:00AM Anavex Life Sciences Announces Commitment for Financial Investment by Shake It Up Foundation for Parkinson’s Research for Clinical Trial of ANAVEX®2-73 (Blarcamesine) in Patients with Parkinson’s
Aug 6, 2020 07:00AM Anavex Life Sciences Reports Fiscal 2020 Third Quarter Financial Results And Provides Business Updates
Aug 5, 2020 05:36PM Anavex Life Sciences (AVXL) Receives TGA Special Access Scheme Approval for ANAVEX®2-73 (blarcamesine) for Alzheimer’s Disease Patients
View More Recent Stories View Older Stories